Analysts have been eager to weigh in on the Healthcare sector with new ratings on Denali Therapeutics (DNLI – Research Report), BridgeBio Pharma (BBIO – Research Report) and 23andMe Holding (ME – Research Report).
Denali Therapeutics (DNLI)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Denali Therapeutics, with a price target of $105.00. The company’s shares closed last Wednesday at $16.95, close to its 52-week low of $15.45.
According to TipRanks.com, Fein is a 4-star analyst with an average return of
Currently, the analyst consensus on Denali Therapeutics is a Strong Buy with an average price target of $52.60, representing a 216.9% upside. In a report issued on January 31, Citi also maintained a Buy rating on the stock with a $32.00 price target.
See today’s best-performing stocks on TipRanks >>
BridgeBio Pharma (BBIO)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on BridgeBio Pharma today and set a price target of $47.00. The company’s shares closed last Wednesday at $33.77.
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of
Currently, the analyst consensus on BridgeBio Pharma is a Strong Buy with an average price target of $48.38, representing a 42.2% upside. In a report issued on January 24, Citi also maintained a Buy rating on the stock with a $42.00 price target.
23andMe Holding (ME)
According to TipRanks.com, Lebovitz is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 23andMe Holding with a $1.43 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DNLI:
- Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
- Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
- Denali Therapeutics announces key anticipated 2024 milestones, priorities
- Denali Therapeutics initiated with bullish view at Citi, here’s why
- Denali Therapeutics initiated with bullish view at Citi
